SCHEMBL6398355

SCHEMBL6398355

CC(CC(O)c1c(O)cc(O)cc1OP(=O)(O)O)c1ccc(O)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 2/20 0.34
ESR2 Q92731 2/20 0.34
INPPL1 O15357 5/20 0.33
INPP5A Q14642 3/20 0.33
INPP5B P32019 1/20 0.33
MIF P14174 1/20 0.31
ALDH1A1 P00352 1/20 0.31
HTR1A P08908 1/20 0.31
THPO P40225 1/20 0.31
BLM P54132 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
NMUR2 Q9GZQ4 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
KDM4E B2RXH2 1/20 0.31
CYP2C9 P11712 1/20 0.31
HIF1A Q16665 1/20 0.31
TAAR1 Q96RJ0 1/20 0.31
AKT1 P31749 1/20 0.30
CYP3A4 P08684 1/20 0.30
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6397995 0.87 HIF1A (0.36) INPPL1INPP5AINPP5BMIFHTR1A
SCHEMBL6397337 0.85 INPPL1 (0.38) ESR1ESR2INPPL1INPP5AINPP5B
SCHEMBL6395991 0.82 ESR1 (0.36) ESR1ESR2INPPL1INPP5AINPP5B
SCHEMBL7615263 0.82 ESR1 (0.42) ESR1ESR2INPPL1INPP5AINPP5B
SCHEMBL6397735 0.81 INPPL1 (0.35) ESR1ESR2INPPL1INPP5AINPP5B
SCHEMBL6396454 0.81 ESR1 (0.36) ESR1ESR2MIFALDH1A1HTR1A
SCHEMBL6401050 0.81 INPPL1 (0.37) ESR1INPPL1INPP5AINPP5BALDH1A1
SCHEMBL6397019 0.80 ESR1 (0.36) ESR1ESR2INPPL1INPP5AINPP5B
SCHEMBL6396820 0.79 ESR1 (0.44) ESR1ESR2INPPL1INPP5AINPP5B
SCHEMBL6397849 0.79 ESR1 (0.43) ESR1ESR2INPPL1INPP5AINPP5B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans PEERCE BRIAN E (US) 2005-08-25 US disclosed
US-6787528-B2 THERAPY FOR KIDNEY DISEASES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2004-09-07 US disclosed
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2003-08-28 US disclosed
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation PEERCE BRIAN E (US) 2002-09-19 US disclosed
US-6355823-B1 MEMBRANE SUBSTRATE PHOSPHATED FOR DRUGS FOR GASTROINTESTINAL DISORDERS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2002-03-12 US disclosed
EP-1175425-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2002-01-30 EP disclosed
WO-2000043402-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2000-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 ESR1 2885/4885ESR2 2416/4885INPPL1 82/4885
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation SLC10A2, SLC34A3, SLC34A1 ESR1 3212/4885ESR2 2699/4885INPPL1 85/4885
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 ESR1 2885/4885ESR2 2416/4885INPPL1 82/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.